Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | sEphB4-HSA |
Trade Name | |
Synonyms | |
Drug Descriptions |
sEphB4-HSA is a fusion protein that consists of the extracellular domain of human ephrin type-B receptor 4 (EphB4) and human serum albumin (HSA), which acts as a decoy to inhibit EphB4 signaling, leading to inhibition of tumor cell growth (PMID: 23721559, PMID: 25148033, PMID: 27941840). |
DrugClasses | EPHB4 Inhibitor 6 |
CAS Registry Number | NA |
NCIT ID | C102569 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + sEphB4-HSA | Bevacizumab sEphB4-HSA | 0 | 0 |
Cetuximab + sEphB4-HSA | Cetuximab sEphB4-HSA | 0 | 1 |
Cytarabine + sEphB4-HSA | Cytarabine sEphB4-HSA | 0 | 1 |
Paclitaxel + sEphB4-HSA | Paclitaxel sEphB4-HSA | 0 | 0 |
Pembrolizumab + sEphB4-HSA | Pembrolizumab sEphB4-HSA | 0 | 3 |
sEphB4-HSA | sEphB4-HSA | 0 | 3 |
sEphB4-HSA + Vincristine sulfate liposome | Vincristine sulfate liposome sEphB4-HSA | 0 | 1 |